key: cord-1032054-7m407tsk
authors: Zuin, Marco; Engelen, Matthias M.; Barco, Stefano; Spyropoulos, Alex C.; Vanassche, Thomas; Hunt, Beverley J.; Vandenbriele, Christophe; Verhamme, Peter; Kucher, Nils; Rashidi, Farid; Zuliani, Giovanni; Konstantinides, Stavros V.; Roncon, Loris
title: Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis
date: 2021-12-07
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.11.029
sha: 7ecc980714604b794700d30f1a8e3ef676bf3d98
doc_id: 1032054
cord_uid: 7m407tsk

nan

During the COVID-19 pandemic, investigations have reported a high incidence of venous thromboembolic (VTE) events in hospitalized patients with coronavirus disease 2019 (COVID- 19) , often despite thromboprophylaxis [1, 2] . However, the risk of hospital-associated VTE extends from the time of admission and over the first 90 days post hospital discharge also in COVID-19 patients. [2] [3] [4] [5] [6] . To this regard, the actual post-discharge cumulative incidence of VTE events in patients hospitalized for COVID-19 pneumonia has not been clearly determined, limiting the formulation of clinical recommendations regarding the need for and optimal duration of extended thromboprophylaxis strategies. The aim of this systematic review and meta-analysis is to estimate the incidence of VTE after hospital discharge among COVID-19 patients.

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses The occurrence of symptomatic or asymptomatic VTE events was chosen as the primary outcome and defined as events diagnosed within a maximum of 180 days post discharge (maximum follow-up length of revised studies) after index hospitalisation. Sub-group analyses evaluating the incidence of acute pulmonary embolism (PE) and deep vein thrombosis (DVT) were also carried out as secondary outcome.

abstracts, editorials/letters, and case series with less than 10 participants were excluded. Data extraction was independently conducted by two authors (M.Z., G.R.). Studies were excluded from the meta-analysis if they did not provide data regarding the incidence of VTE events post-discharge after COVID-19 infections. For all studies reviewed we extracted the number of patients enrolled, the mean age, male gender, prevalence of potential VTE risk factors (if reported), length of follow-up, the number of VTE events as well as the number of PE and/or DVT cases when specified. The quality of included studies was graded using the Newcastle-Ottawa quality assessment scale.

The cumulative post-COVID-19 incidence of VTE events (n/N), defined as the ratio between patients experiencing VTE (n) and the number of patients enrolled in each study (N) over the follow-up period were pooled using a random effects model and presented with the corresponding 95% confidence interval (CI). Statistical heterogeneity was measured using the Higgins I 2 statistic and Q value. A predefined sensitivity analysis (leave-one-out analysis) was performed removing 1 study at the time.

To evaluate the presence of publication bias both funnel plot and Egger's test were computed.

Moreover, to further appraise the impact of potential baseline confounders, a meta-regression analysis using the patient's clinical characteristics, VTE risk factors, intensive care unit (ICU) admission and length of follow-up were used as moderator variables. All meta-analyses were conducted using Comprehensive Meta-Analysis software, version 3 (Biostat, USA).

A total of 266 articles were obtained using our search strategy. After excluding duplicates and preliminary screening, 96 full-text articles were assessed for eligibility, 87 studies were excluded for not meeting the inclusion criteria and 2 records were identified using other sources, leaving 11 investigations fulfilling the inclusion criteria (Supplementary File 2) [3-5; 7-14] .

Overall, 18,949 COVID-19 patients were included in this analysis (Table 1) . Only four analyses reported the mean hospitalization length, which was 19.5 days [3, 4, 11, 3] . Few investigations reported data regarding the administration of post-discharge prophylactic or therapeutic J o u r n a l P r e -p r o o f Journal Pre-proof anticoagulation [3-5, 10-12, 14] . Eight studies also reported the rate of intensive care unit (ICU) admission during index hospitalisation [4, 5, 8, [10] [11] [12] [13] [14] . The mean length of follow-up was 61.7 days and follow-up duration ranged between 21 and 180 days. Quality assessment showed that all studies were of moderate-high quality according to the NOS scale (Supplementary file 3).

The cumulative post-discharge rate of VTE in COVID-19 patients ranged between 0.2 to 14.8% among the reviewed studies [3-5; 7-14] . A random effect model revealed a pooled incidence of post COVID-19 VTE in 1.8% of cases (95% CI: 0.8-4.1%, I 2 =96.0%) (Figure 1, A) . Only four studies, including 2,518 patients, reported the mean time between COVID-19 discharged and VTE onset, which was 13.5 days [3, 8, 10, 12] . Sensitivity analysis slightly changed the combined incidence rate, which remained statistically significant across a range from 1.5% of cases (95% CI: 0.5-3.0, I 2 :96.0%) to 2.0% of cases (95% CI: 0.8-4.7, I 2 :96.3%), suggesting that no single investigation had an undue impact on the study outcome. Both the visual inspection of the funnel plot (Supplementary file 4) and the Egger's tests revealed no evidence of publication bias (t=0.254, p=0.804). A further sub-analysis based only on those studies enrolling more than one-hundred patients [10-12, 15, 16, 18, 20-22] confirmed yielded results, showing a VTE incidence of 1.63% (95% CI:0.4-2.0%, p<0.0001, I 2 : 96.0%).

Not all studies differentiated between acute PE and DVT. Nine studies (n=9,199) reported the incidence of post-discharge PE after COVID-19 hospitalization, ranging between 0.2 and 5.6% [3-5; 7; 8-12; 14] . The pooled cumulative post-discharge PE incidence was 1.5% (95% CI: 0.5 -4.0, I 2 :93.4%) ( Figure 1, B) . On the other hand, only five studies reported the incidence of post-discharge DVT after COVID-19 hospitalization, which ranged between 0.1 to 2.6% [4, 8, 11, 12, 14] (n=7,395). In these patients, the pooled cumulative post-discharge DVT incidence was 0.9% (95% CI:0.3 to 2.1, I 2 =78.4%) ( Figure 1, C) .

Meta-regression analysis revealed that the post-discharge incidence of VTE events was directly affected by age (p=0.03) and male gender (p=0.04) and inversely correlated with the length of followup period (p=0.012). Conversely, no associations were identified using post-discharge J o u r n a l P r e -p r o o f Journal Pre-proof thromboprophylaxis (p=0.20), cancer (p=0.14), VTE history (p=0.82), ICU admission (p=0.55) and mean length of hospitalization (p=0.68).

In this study, the pooled VTE incidence of VTE among COVID-19 patients within weeks of hospital discharge was 1.8%, which appears higher than other groups of medically ill patients [15] .

Indeed, compared to the MARINER trial, the rate of 1.8% found in our study is at least 4-fold higher, which is very much in line with in-hospital data suggesting a 2-to-5-fold increased risk of VTE in the hospital phase compared to pre-COVID populations.

However, this finding resulted from very heterogeneous rates described in individual studies, which may have been due to differences in VTE screening strategies and should carefully interpreted.

Indeed, it is possible that differences in follow-up strategies and presence of an immunothrombosis may have led to "overdiagnosis" of VTE in critically ill COVID-19 patients.

Most of the VTE events collected in this analysis were diagnosed early after hospital discharge, indicating that their onset depends on the changes during acute COVID-19 and on hospitalizationrelated risk factors. The high heterogeneity observed was partially explained by the meta-regression which supported the already previously observed relationship between VTE events and some demographical factors, such as age and male sex, as potential risk factors for VTE events in patients with COVID-19, as it is for non-COVID-19 patients [16, 17]. The pathogenesis of VTE events in COVID-19 patients seems to be different and in part overlapping with "traditional" ones. Indeed, two different pathways may be identified: the former is represented by the onset of "immunothrombosis" triggered by the viral infection while the latter by the presence of "classic" major transient provoking risk factors, such as bed rest, the presence of catheters, cancer and hypoxemia, as well as age and the presence of concomitant conditions. Moreover, local endothelial cell dysfunction in the pulmonary J o u r n a l P r e -p r o o f Journal Pre-proof microvasculature also seems to play a substantial role in the thromboinflammatory processes. As evidenced by our meta-regression, it seems that the second pathways predominate on the first after the resolution of the infection.

Due to the limited data provided in the reviewed manuscripts this study cannot answer the question whether extended anticoagulation may be useful for minimizing the risk of thromboembolic events after hospital discharge. In some of the reports reviewed extended thromboprophylaxis was not prescribed accordingly with current guidelines, which recommend a case-by-case evaluation, balancing the bleeding versus thrombotic risk [18] . In others, thromboprophylaxis was prescribed to a proportion of patients: therefore, our estimate may represent an underestimation of the background risk of post-discharge VTE in patients hospitalised with COVID-19. Current recommendations from the American College of Chest Physicians (ACCP) guidelines suggest that a VTE event rate ≥ 1% is sufficient to warrant pharmacologic prophylaxis in medically ill patients: although our post-discharge VTE incidence overcomes this threshold [19] , our data must be considered preliminary and cannot be directly translated into clinical practice. In a large prospective registry (CORE-19) use of postdischarge anticoagulation was associated with a 46% reduction in post discharge major thromboembolic events and mortality [14] . Prospective placebo-controlled randomized trials are needed to answer this question and are underway although one trial is poorly recruiting (i.e., ACTIVE-4c, Trial N° NCT04505774). Results from the randomized MICHELLE trial, using enrichment criteria and screening methods in hospitalized COVID-19 patients, did reveal an elevated risk of thromboembolism and a significant 67% RRR (9.43% to 3.14%, relative risk 0·33; 95% confidence interval [CI]: 0·12-0·90, p=0.029) of major and fatal thromboembolic events favouring the direct oral anticoagulant rivaroxaban over no anticoagulation at day 35 post-hospital discharge, without increasing the bleeding events [20] . It should be noted that only one study systematically screened all patients for DVT and selected high-risk patients for PE [4] while the other reviewed reported only clinical events with patients undergoing computed tomography pulmonary angiography or lower limb ultrasound when reporting worsening of symptoms.

Our study has several limitations related to the observational nature of the studies reviewed and their own limitations with all inherited bias. Potential underestimation could derive from detection bias if patients were not systematically screened for VTE. Moreover, sampling bias by the competing risk of death may also have led to underestimation of the real cumulative incidence of thromboembolic events. We cannot assess if an adequate prophylactic anticoagulation was consistently administered as well as the outcome in patients receiving an extended thromboprophylaxis because these data were not systematically provided.

In conclusion, our study evidenced that the pooled incidence of VTE events among COVID-19 patients in the post-discharge period was elevated and estimated to be 1.8%, with acute PE representing the most frequent type of venous thromboembolic complication. 

Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California

Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

Postdischarge thrombosis and hemorrhage in patients with COVID-19

Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

Venous thromboembolismrelated readmission in emergency general surgery patients: a role for prophylaxis on discharge?

Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study

Postdischarge venous thromboembolism following hospital admission with COVID-19

Pulmonary thrombosis in Covid-19: before, during and after hospital admission

Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection

Puerta de Hierro Hospital Admission Study Group. Hospital Readmissions of Discharged Patients with COVID-19

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up

Surviving COVID-19 in Bergamo province: a post-acute outpatient reevaluation

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19

Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification

Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial

Study design Number of patients

Males, %

Thromboprophylaxis N, (%)